The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and potentially unreliable paper-based ...

AI—both generative and machine learning/statistical—is essentially dead in the water without well-vetted, timely, quality data. This is holding back AI efforts more than anticipated, a recent survey ...

Artificial intelligence is no longer an emerging technology—it is an embedded reality shaping the way we live, govern and do business. From predictive healthcare to autonomous defense systems, AI is ...

Doubt is hampering data-driven decision making, as CIOs consider how to make the most of generative AI. This is according to recent research from The Center for Applied AI and Business Analytics at ...

Data is one of an organization’s most valuable assets, yet it is one of its most vulnerable, and AI is introducing more risk.

Data integrity challenges faced by a number of pharma industries in developing and third world countries including India are mainly due to non-compliance of GxP (good variable factor practices) ...